Fried Frank's role in Celgene's acquisition of Abraxis BioScience reported in <em>New York Law Journal</em>

Fried Frank's role in Celgene's acquisition of Abraxis BioScience reported in New York Law Journal

New York Law Journal noted the Firm's representation of Abraxis BioScience Inc. in connection with its US$2.8b acquisition by Celgene Corporation in its "New Deals" column. Leading the Fried Frank team were corporate partners Phillip Richter (NY) and Brian T. Mangino (DC) and tax partners Alan S. Kaden (DC) and Michael J. Alter (DC).

news-detail.inc